Estimates of radiation-absorbed dose to kidneys in patients treated with 90Y-ibritumomab tiuxetan.
Estimates of radiation-absorbed dose to kidneys in patients treated with 90Y-ibritumomab tiuxetan.
复制标题
使用 90Y-ibritumomab tiuxetan 治疗的患者肾脏辐射吸收剂量的估计。
DOI：
10.1089/cbr.2008.0506
复制
发表时间：
2008
影响因子：
3.4
通讯作者：
Sgouros,George
中科院分区：
文献类型：
--
作者：
Baechler,Sébastien;Hobbs,RobertF;Prideaux,AndrewR;Recordon,Mélanie;Bischof-Delaloye,Angelika;Sgouros,George
The aim of the present study was to retrospectively estimate the absorbed dose to kidneys in 17 patients treated in clinical practice with90Y-ibritumomab tiuxetan for non-Hodgkin's lymphoma, using appropriate dosimetric approaches available.Methods:The single-view effective point source method, including background subtraction, is used for planar quantification of renal activity. Since the high uptake in the liver affects the activity estimate in the right kidney, the dose to the left kidney serves as a surrogate for the dose to both kidneys. Calculation of absorbed dose is based on the Medical Internal Radiation Dose methodology with adjustment for patient kidney mass.Results:The median dose to kidneys, based on the left kidney only, is 2.1 mGy/MBq (range, 0.92–4.4), whereas a value of 2.5 mGy/MBq (range, 1.5–4.7) is obtained, considering the activity in both kidneys.Conclusions:Irrespective of the method, doses to kidneys obtained in the present study were about 10 times higher than the median dose of 0.22 mGy/MBq (range, 0.00–0.95) were originally reported from the study leading to Food and Drug Administration approval. Our results are in good agreement with kidney-dose estimates recently reported from high-dose myeloablative therapy with90Y-ibritumomab tiuxetan.
